What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness ...

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

The USA’s Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Moderna (MRNA) stock is in focus as CEPI vaccine coalition agreed to invest up to $54.3M to support a late-stage trial for the company's bird flu shot. Read more here.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...